Literature DB >> 24013219

Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.

Akiko Takahashi1, Genichiro Ishii, Tomonari Kinoshita, Tatsuya Yoshida, Shigeki Umemura, Tomoyuki Hishida, Kiyotaka Yoh, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Yuichiro Ohe, Kanji Nagai, Atsushi Ochiai.   

Abstract

PURPOSE: The immunophenotypes of cancer stromal cells have been recognized as prognostic factors of cancer. The purpose of this study was to analyze the prognostic markers of high-grade neuroendocrine carcinomas of the lung (HGNEC; both small cell carcinoma and large cell neuroendocrine carcinoma) by examining the immunophenotypes of cancer stromal cells.
MATERIALS AND METHODS: One hundred and fifteen patients who underwent a complete resection of HGNEC were included in this study. We examined the presence of CD204-positive tumor-associated macrophages (TAMs), Foxp3-positive regulatory T cells (Tregs), and podoplanin-positive cancer-associated fibroblasts (CAFs) to evaluate the prognostic values of these markers.
RESULTS: The number of CD204-positive TAMs and Foxp3-positive Tregs did not influence the overall survival (OS) or the relapse-free survival (RFS) of the patients. However, patients with podoplanin-positive CAFs had a significantly better prognosis than those with podoplanin-negative CAFs [OS: p = 0.002, RFS: p = 0.002, 5-year overall survival (5YR): 74 vs. 45 %]. According to subgroup analyses, patients with podoplanin-positive CAFs displayed a better prognosis for both small cell carcinoma (OS: p = 0.046, 5YR: 74 vs. 46 %) and large cell neuroendocrine carcinoma (OS: p = 0.020, 5YR: 74 vs. 45 %). Moreover, in multivariate analyses, the podoplanin status of the CAFs was shown to be a statistically significant independent predictor of recurrence.
CONCLUSION: The presence of podoplanin-positive CAFs had a favorable prognostic value, suggesting that the evaluation of podoplanin expression by CAFs would lead to a novel risk classification of patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24013219     DOI: 10.1007/s00432-013-1502-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  39 in total

Review 1.  Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

2.  Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung.

Authors:  Jitsuo Usuda; Shuji Ichinose; Taichirou Ishizumi; Keishi Ohtani; Tatsuya Inoue; Hisashi Saji; Masahiro Kakihana; Naohiro Kajiwara; Osamu Uchida; Masaharu Nomura; Hidemitsu Tsutsui; Tatsuo Ohira; Norihiko Ikeda
Journal:  Lung Cancer       Date:  2010-11-13       Impact factor: 5.705

3.  Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery.

Authors:  Jitsuo Usuda; Shuji Ichinose; Taichirou Ishizumi; Keishi Ohtani; Tatsuya Inoue; Hisashi Saji; Masatoshi Kakihana; Naohiro Kajiwara; Osamu Uchida; Masaharu Nomura; Tatsuo Ohira; Norihiko Ikeda
Journal:  Lung Cancer       Date:  2011-05-06       Impact factor: 5.705

4.  Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

Authors:  Giulio Rossi; Alberto Cavazza; Alessandro Marchioni; Lucia Longo; Mario Migaldi; Giuliana Sartori; Nazzarena Bigiani; Laura Schirosi; Christian Casali; Uliano Morandi; Nicola Facciolongo; Antonio Maiorana; Mario Bavieri; Leonardo M Fabbri; Elisabeth Brambilla
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.

Authors:  Shigeo Yamazaki; Ikuo Sekine; Yoshihiro Matsuno; Hidefumi Takei; Noboru Yamamoto; Hideo Kunitoh; Yuichiro Ohe; Tomohide Tamura; Tetsuro Kodama; Hisao Asamura; Ryosuke Tsuchiya; Nagahiro Saijo
Journal:  Lung Cancer       Date:  2005-03-17       Impact factor: 5.705

6.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

7.  Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.

Authors:  Satoshi Igawa; Reiko Watanabe; Ichiro Ito; Haruyasu Murakami; Toshiaki Takahashi; Yukiko Nakamura; Asuka Tsuya; Kyoichi Kaira; Tateaki Naito; Masahiro Endo; Nobuyuki Yamamoto; Toru Kameya
Journal:  Lung Cancer       Date:  2009-08-21       Impact factor: 5.705

8.  Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma.

Authors:  Akikazu Kawase; Genichiro Ishii; Kanji Nagai; Takeo Ito; Tatsuya Nagano; Yukinori Murata; Tomoyuki Hishida; Mitsuyo Nishimura; Junji Yoshida; Kazuya Suzuki; Atsushi Ochiai
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

9.  Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype.

Authors:  Shotaro Ono; Genichiro Ishii; Kanji Nagai; Teruhisa Takuwa; Junji Yoshida; Mitsuyo Nishimura; Tomoyuki Hishida; Keiju Aokage; Satoshi Fujii; Norihiko Ikeda; Atsushi Ochiai
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

10.  Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas.

Authors:  Filomena M Carvalho; Fabricia L Zaganelli; Bernardo G L Almeida; Joao Carlos Sampaio Goes; Edmund C Baracat; Jesus P Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

View more
  7 in total

1.  The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung.

Authors:  Keigo Sekihara; Tomoyuki Hishida; Shinnosuke Ikemura; Koichi Saruwatari; Masahiro Morise; Takeshi Kuwata; Satoshi Fujii; Motohiro Kojima; Atsushi Ochiai; Kazuhito Funai; Keiju Aokage; Junji Yoshida; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-22       Impact factor: 4.553

2.  Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth.

Authors:  Akiko Takahashi; Genichiro Ishii; Shinya Neri; Tatsuya Yoshida; Hiroko Hashimoto; Shigeki Suzuki; Shigeki Umemura; Shingo Matsumoto; Kiyotaka Yoh; Seiji Niho; Koichi Goto; Hironobu Ohmatsu; Kanji Nagai; Akihiko Gemma; Yuichiro Ohe; Atsushi Ochiai
Journal:  Oncotarget       Date:  2015-04-20

3.  Inverse role of distinct subsets and distribution of macrophage in lung cancer prognosis: a meta-analysis.

Authors:  Pin Wu; Dang Wu; Lufeng Zhao; Lijian Huang; Gang Chen; Gang Shen; Jian Huang; Ying Chai
Journal:  Oncotarget       Date:  2016-06-28

Review 4.  Podoplanin in Inflammation and Cancer.

Authors:  Miguel Quintanilla; Lucía Montero-Montero; Jaime Renart; Ester Martín-Villar
Journal:  Int J Mol Sci       Date:  2019-02-06       Impact factor: 5.923

5.  Podoplanin-positive cancer-associated fibroblasts predict poor prognosis in lung cancer patients.

Authors:  Guoming Hu; Kefang Zhong; Wei Chen; Shimin Wang; Liming Huang
Journal:  Onco Targets Ther       Date:  2018-09-10       Impact factor: 4.147

6.  Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.

Authors:  Akiko Takahashi; Masahiro Seike; Mika Chiba; Satoshi Takahashi; Shinji Nakamichi; Masaru Matsumoto; Susumu Takeuchi; Yuji Minegishi; Rintaro Noro; Shinobu Kunugi; Kaoru Kubota; Akihiko Gemma
Journal:  Sci Rep       Date:  2018-10-05       Impact factor: 4.379

Review 7.  Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?

Authors:  Elisa Giannetta; Anna La Salvia; Laura Rizza; Giovanna Muscogiuri; Severo Campione; Carlotta Pozza; Annamaria Anita LIvia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.